The State of the Art of the Application of Tools and Methods for -Omics Data Integration and Microbiota-Related Diseases in Both Human and Animal Models
A special issue of BioTech (ISSN 2673-6284).
Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 224
Special Issue Editor
Interests: gene variants linked to diseases; genomics; transcriptomics; metagenomics; cardiovascular disease; cardiomyopathies; pulmonary hypertension
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Over the last 15 years, closely related to metabolism, immune response, and inflammation, microbiota dysbiosis has been associated with several disorders with multifactorial etiologies, such as inflammatory bowel disease, autoimmune diseases, affective and neurodevelopmental disorders, cancer, and cardiovascular diseases. Therefore, microbiota characterization, together with genome, epigenome, metabolome, transcriptome, and proteome characterization in both hosts and their microbiota are considered key elements to investigate in the triggering of diseases.
Interest in multi-omics integrative approaches is growing in order to understand the molecular mechanisms underlying both normal physiology and complex diseases, due to the key relationship between molecule types in both microorganisms and hosts. However, quality data acquisition, analysis, and, most importantly, data integration and interpretation are difficult to achieve, although several promising tools and methods are being developed for this purpose.
This Special Issue on "microintegromics" will focus on the state of the art of the application of tools and methods for -omics data integration and microbiota-related diseases in human and animal models. There are several questions in this field to be investigated, including the contribution of microbiota (bacteria, virus, and fungi) to complex disease (cause, consequence) or disease evolution (infection, co-infection); the mechanisms linking microbiota, metabolites, the immune system, and disease; the potential of microbiota or microbiota-derived molecules to be disease biomarkers; and the identification of new therapy targets and microbiota interactions. Manuscripts addressing these issues are welcome.
Dr. Ana Isabel Fernández
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioTech is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
